Inhibikase Therapeutics (IKT) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 26, 2026, with shareholders able to vote online, by phone, or by mail.

• Shareholders of record as of April 27, 2026, are eligible to vote on six key proposals, including director elections, auditor ratification, amendments to the certificate of incorporation and equity plan, and advisory votes on executive compensation.

• The board recommends voting for all proposals and for annual (one-year) frequency on future say-on-pay votes.

Voting matters and shareholder proposals

• Election of two Class III directors, Arvind Kush and Dennis Berman, to serve until 2029.

• Ratification of CohnReznick LLP as independent auditor for fiscal year 2026.

• Amendment to the certificate of incorporation to limit liability of certain officers as permitted by Delaware law.

• Amendment to the 2020 Equity Incentive Plan to increase shares reserved for issuance by 3,000,000.

• Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes.

• Shareholder proposals and nominations for the 2027 meeting must be submitted by specified deadlines.

Board of directors and corporate governance

• The board consists of seven members divided into three staggered classes, with only one class up for election each year.

• All non-employee directors are independent under Nasdaq and SEC rules, except the CEO.

• Three standing committees: audit, compensation, and corporate governance/nominating, each fully independent.

• The board encourages diversity of experience and skills, and considers stockholder nominations.